Disposition of 1337 shares by Ming Hsieh of Fulgent Genetics at 21.61 subject to Rule 16b-3
| FLGT Stock | USD 16.96 0.67 3.80% |
Slightly above 62% of Fulgent Genetics' investor base is looking to short. The analysis of overall sentiment of trading Fulgent Genetics stock suggests that many investors are alarmed at this time. Fulgent Genetics' investing sentiment can be driven by a variety of factors including economic data, Fulgent Genetics' earnings reports, geopolitical events, and overall market trends.
Fulgent |
Filed transaction by Fulgent Genetics Director, 10 Percent Owner, Officer: Chief Executive Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at finance.yahoo.com
 |
Fulgent Genetics Fundamental Analysis
We analyze Fulgent Genetics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fulgent Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fulgent Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Fulgent Genetics is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Fulgent Genetics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Fulgent Genetics stock to make a market-neutral strategy. Peer analysis of Fulgent Genetics could also be used in its relative valuation, which is a method of valuing Fulgent Genetics by comparing valuation metrics with similar companies.
Peers
Fulgent Genetics Related Equities
| TTOO | T2 Biosystms | 8.70 | ||||
| GH | Guardant Health | 4.59 | ||||
| TWST | Twist Bioscience | 1.83 | ||||
| WAT | Waters | 1.09 | ||||
| CDNA | Caredx | 1.03 | ||||
| MTD | Mettler Toledo | 0.80 | ||||
| EXAS | EXACT Sciences | 0.62 | ||||
| DHR | Danaher | 0.61 | ||||
| TMO | Thermo Fisher | 0.05 | ||||
| NTRA | Natera | 0.06 | ||||
| A | Agilent Technologies | 0.1 | ||||
| CRL | Charles River | 0.81 | ||||
| ILMN | Illumina | 3.99 |
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.